HSCT-Based Approaches for Tolerance Induction in Renal Transplant

Area of Science:

• Immunology
• Transplantation Medicine
• Regenerative Medicine

Background:

• Renal transplantation is the leading treatment for end-stage kidney failure, but long-term success is limited by immunosuppression toxicities and alloimmunity.
• Current immunosuppressive strategies result in approximately 50% of patients not surviving at 10 years post-transplant.
• Cell-based therapies offer a novel approach to overcome these limitations and improve patient outcomes.

Purpose of the Study:

• To review the preclinical advancements and current clinical data on cell-based therapies for inducing immune tolerance in renal transplantation.
• To highlight the potential of these therapies to enhance long-term graft survival and patient longevity.
• To discuss strategies involving hematopoietic stem cells, regulatory T cells, and facilitating cells to harness the donor immune system.

Main Methods:

• Preclinical studies in various animal models (mouse, swine, canine, nonhuman primate) to develop cell-based tolerance induction strategies.
• Clinical trials investigating protocols combining traditional immunosuppressants with cell populations like hematopoietic stem cells and regulatory T cells.
• Analysis of current clinical data from global research groups on the efficacy and feasibility of cell-based therapies.

Main Results:

• Cell-based therapies have demonstrated success in facilitating chimerism and achieving tolerance in preclinical models with major histocompatibility disparity.
• Early clinical trials show promising results, indicating the feasibility and benefits of applying cell-based therapies in renal transplant recipients.
• These approaches aim to utilize the donor's immune system to protect the transplanted organ, reducing the need for long-term immunosuppression.

Conclusions:

• Cell-based therapies represent a significant advancement in transplantation, offering a path towards improved long-term patient and graft survival.
• Inducing immune tolerance through cell-based strategies can mitigate the adverse effects of conventional immunosuppression.
• Ongoing clinical trials are crucial for validating these promising approaches and translating them into standard clinical practice.